D. E. Shaw & Co., Inc. Cullinan Oncology, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 61,621 shares of CGEM stock, worth $997,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,621

Previous 48,919 25.97%

Holding current value

$997,027

Previous $498,000 110.84%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.17 - $19.02 $129,179 - $241,592	12,702 Added 25.97%	61,621 $1.05 Million
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $72,722 - $94,289	9,217 Added 23.22%	48,919 $498,000
Q3 2023 Nov 14, 2023	SELL	$9.05 - $11.72 $146,999 - $190,367	-16,243 Reduced 29.03%	39,702 $359,000
Q2 2023 Aug 14, 2023	SELL	$8.8 - $13.4 $155,117 - $236,201	-17,627 Reduced 23.96%	55,945 $601,000
Q1 2023 May 15, 2023	SELL	$10.2 - $11.91 $266,515 - $311,196	-26,129 Reduced 26.21%	73,572 $752,000

Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $216,376 - $303,194	22,261 Added 28.75%	99,701 $1.05 Million
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $207,393 - $270,559	-17,546 Reduced 18.47%	77,440 $993,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $13.55 $694,347 - $1.29 Million	94,986 New	94,986 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$22.56 - $29.68 $1.36 Million - $1.79 Million	-60,319 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$24.96 - $41.25 $92,701 - $153,202	-3,714 Reduced 5.8%	60,319 $1.55 Million
Q1 2021 May 17, 2021	BUY	$28.0 - $53.42 $1.79 Million - $3.42 Million	64,033 New	64,033 $2.67 Million

Others Institutions Holding CGEM

# of Institutions

118

Shares Held

42.8M

Call Options Held

12.6K

Put Options Held

4.9K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $738M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account